Scientists uncover mechanisms of potential COVID-19 drug targets
Researchers have used CRISPR and cryogenic electron microscopy to unravel the workings of two receptors involved in diseases such as cancer and COVID-19.
List view / Grid view
Researchers have used CRISPR and cryogenic electron microscopy to unravel the workings of two receptors involved in diseases such as cancer and COVID-19.
A new study sequenced tumour DNA for the “ultrasensitive” detection of HPV, further honing precision treatment of the illness.
An artificial intelligence technique can identify which neoantigens are recognised by the immune system, possibly improving cancer prognosis and treatment.
New research has revealed that club cells secret anti-immunosuppressive factors in tumours, potentially revolutionising cancer therapies.
Researchers have developed a new method that can rapidly count the number of T cells in a tumour, helping to predict patient response to therapies.
An imaging technique identified emerging drugs that activate the STING protein to alter metabolic pathway activity in cancer cells.
Researchers have created a tool that allows glycomics datasets to be analysed using artificial intelligence for early cancer diagnoses.
Targeting stem-like T cells within certain lymph nodes could improve the number of cancer patients that respond to immunotherapy treatments.
A new study found that the RNA RN7SL1 can activate T cells to seek out cancer cells, potentially improving cellular treatments.
Researchers are investigating how high-intensity focused ultrasound (HIFU) can work on a cellular level to treat a range of cancers.
A new study has identified a vital enzyme, known as APOBEC3A, that could lead to new treatments against cancers and viral infections.
NICEdrug.ch is an open-access database that may help scientists assess potential drugs for a range of diseases more quickly.
Researchers have discovered a therapeutic agent that is effective in vitro at disrupting a biological pathway that helps cancer survive.
Researchers identified a potential therapeutic involving the inhibition of PIP4K enzymes which could enable the immune system to destroy tumour cells.
Researchers have used patient-specific tumour organoid models to improve immunotherapy treatments for appendiceal cancer.